Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.

about

Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.

Item

http://www.wikidata.org/entity/Q49307383

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Real-world usage and clinical ...... ng cancer patients in the USA.

@en

Real-world usage and clinical ...... ng cancer patients in the USA.

@nl

type

Item

label

Real-world usage and clinical ...... ng cancer patients in the USA.

@en

Real-world usage and clinical ...... ng cancer patients in the USA.

@nl

prefLabel

Real-world usage and clinical ...... ng cancer patients in the USA.

@en

Real-world usage and clinical ...... ng cancer patients in the USA.

@nl

P1476

Real-world usage and clinical ...... ng cancer patients in the USA.

@en

P2093

Bijal Shah-Manek

http://www.w3.org/2001/XMLSchema#string

Marco D DiBonaventura

http://www.w3.org/2001/XMLSchema#string

Mathias Schulz

http://www.w3.org/2001/XMLSchema#string

P2860

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

P304

75-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S144960

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

William Wong

P577

2017-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29317835

http://www.w3.org/2001/XMLSchema#string

P921

crizotinib

P932

5744742

http://www.w3.org/2001/XMLSchema#string